Dr. Chelsea Trengrove is the CEO and Cofounder of Neoclease, a biotech startup developing gene-specific nucleases designed with generative AI to overcome today’s barriers in precision gene editing. With a PhD in neuroscience and a background leading multimillion-dollar biotech partnerships, Chelsea brings deep scientific insight and business acumen to the forefront of next-generation genetic medicine. Neoclease’s lead program targets LRRK2 for Parkinson’s disease, with a platform poised to transform therapeutic genome editing across a range of indications.